Oncogene AF1q enhances doxorubicin-induced apoptosis through BAD-mediated mitochondrial apoptotic pathway

Molecular Cancer Therapeutics

Volumn 7, Issue 10, 2008, Pages 3160-3168

  Ngai, Na Co ^a   Wing, Pui Tsang ^a   Wong, Timothy W L ^a   Hoi, Hung Cheung ^a   Tsun, Yee Tsang ^a   Siu, Kai Kong ^a   Tim, Tak Kwok ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CASPASE 3; CASPASE 9; CYTOCHROME C; DOXORUBICIN; GAMMA INTERFERON; MESSENGER RNA; PACLITAXEL; PROTEIN BAD; SMALL INTERFERING RNA; AF1Q PROTEIN, HUMAN; ANTISENSE OLIGONUCLEOTIDE; PLASMA PROTEIN; TUMOR PROTEIN;

ALL1 FUSED GENE CHROMOSOME 1A GENE; APOPTOSIS; ARTICLE; CELL STRAIN HEPG2; CELL STRAIN HL 60; CONTROLLED STUDY; DOWN REGULATION; DOWNSTREAM PROCESSING; ENZYME ACTIVATION; ENZYME RELEASE; GAMMA RADIATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; ONCOGENE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MITOCHONDRION; PHOSPHORYLATION; TUMOR CELL LINE; UPREGULATION;

APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BLOOD PROTEINS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOCHONDRIA; NEOPLASM PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; ONCOGENES; PHOSPHORYLATION; TRANSFECTION; UP-REGULATION;

EID: 55749084901     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0416     Document Type: Article

References (26)

1. Tse W, Zhu W, Chen HS, Cohen A. A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. Blood 1995;85:650-6.
2. Tse W, Meshinchi S, Alonzo TA, et al. Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood 2004;104:3058-63.
3. Tse W, Joachim Deeg H, Stirewalt D, Appelbaum FR, Radich J, Gooley T. Increased AF1q gene expression in high-risk myelodysplastic syndrome. Br J Haematol 2005;128:218-20.
4. Jacques C, Baris O, Prunier-Mirebeau D, et al. Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J Clin Endocrinol Metab 2005;90:2314-20.
5. Keshava C, Whipkey D, Weston A. Transcriptional signatures of environmentally relevant exposures in normal human mammary epithelial cells: benzo[a]pyrene. Cancer Lett 2005;221:201-11.
6. Li DQ, Hou YF, Wu J, et al. Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. Eur J Cancer 2006;42:3274-86.
7. el-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 1997;9:79-87.
8. Kwok TT, Sutherland RM. Epidermal growth factor reduces resistance to doxorubicin. Int J Cancer 1991;49:73-6.
9. Chao OS, Clement MV. Epidermal growth factor and serum activate distinct pathways to inhibit the BH3 only protein BAD in prostate carcinoma LNCaP cells. Oncogene 2006;25:4458-69.
10. Arends MJ, McGregor AH, Toft NJ, Brown EJ, Wyllie AH. Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. Br J Cancer 1993;68:1127-33.
11. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-28.
12. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003;22:8999-9006.
13. Tseng YS, Tzeng CC, Chiu AW, et al. Ha-ras overexpression mediated cell apoptosis in the presence of 5-fluorouracil. Exp Cell Res 2003;288:403-14.
14. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-19.
15. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999;15:269-90.
16. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003;112:481-90.
17. Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta 2004;1644:107-13.
18. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995;80:285-91.
19. Kim H, Rafiuddin-Shah M, Tu HC, et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006;8:1348-58.
20. Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 2005;17:617-25.
21. Bergmann A. Survival signaling goes BAD. Dev Cell 2002;3:607-8.
22. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996;87:619-28.
23. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999;286:1358-62.
24. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
25. Harada H, Becknell B, Wilm M, et al. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell 1999;3:413-22.
26. Zhou XM, Liu Y, Payne G, Lutz RJ, Chittenden T. Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. J Biol Chem 2000;275:25046-51.